SLC16A13

Across TCGA pan-cancer cohorts, SLC16A13 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated SLC16A13 data layer compared with 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SLC16A13 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC16A13 expression acts as an unfavorable survival marker, although some lineages such as KIRC and SCLC show a favorable association.

LUAD, MESO, and KIRC are the cancer types where SLC16A13 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.291	0.523	<.001	101	view →
MESO	DFS	Quartile	All	0.220	0.492	<.001	99	view →
KIRC	DFS	Tertile	All	0.701	0.531	<.001	87	view →
ACC	DFS	Median	All	0.390	0.764	<.001	79	view →
SCLC	DFS	Tertile	All	0.760	0.470	<.001	47	view →
KICH	OS	Tertile	III,IV	0.226	0.835	.002	45	view →
CHOL	DFS	Tertile	II,III,IV	0.150	0.625	.002	44	view →
LGG	OS	Median	All	0.365	0.520	<.001	29	view →
BLCA	OS	Tertile	All	0.406	0.645	.006	28	view →
DLBC	DFS	Quartile	All	0.521	1.000	.007	25	view →
COAD	DFS	Median	II,III,IV	0.409	0.641	.005	25	view →
LAML	DFS	Tertile	All	0.435	0.621	.017	24	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

SLC16A13–LUAD (DFS)

Open the LUAD breakdown →